I'll research LDOS before writing the preview. Let me start by gathering recent earnings materials, filings, news, and price data.Let me read the most recent earnings materials (2026Q1) and the year-ago quarter for context.Now let me get the year-ago Q2 comp, recent stock price, and analyst expectations.The stock has fallen dramatically (from ~$198 in Jan to ~$100 in late June, now ~$119). Let me get recent news and analyst expectations to understand the setup.Let me get more context on the stock's sharp decline and recent analyst sentiment.I now have a comprehensive picture. Let me write the preview.
Leidos Holdings (LDOS) — Q2 FY2026 Earnings Preview
Report date: Tuesday, August 4, 2026 (before market open) · Event: Q2 FY2026 Earnings Call
Stock (8/3/26 close): ~$118.75 · Consensus: Revenue ~$4.43B, non-GAAP EPS ~$2.90
The one-sentence setup
LDOS enters this print as a broken momentum story trading at a deep-value multiple: the stock has been cut roughly in half from its January ~$198 high to a late-June low near $100 before a recent bounce to ~$119. Management itself pre-warned that Q2 would be the "low point" of the year for both revenue growth and margin, so the debate is less about the quarter's optics and more about whether the Health segment overhang is a one-year reset or a structural crack — and whether full-year guidance holds.
Why the stock got cut in half
Three overlapping fears drove the derating through 1H26:
- Health "overearning" fears (started January). Stifel downgraded to Hold in early January on concerns that growth from the high-margin VA Compensation & Pension (disability) exams business would moderate in 2026 as the VA backlog normalizes and a fourth vendor enters.
- The DHMSM / MHS GENESIS shock (mid-June). The Defense Health Agency signaled it may reduce its reliance on Leidos as lead systems integrator for the military's electronic health record program — a franchise Leidos architected. This triggered a wave of downgrades (BofA to Neutral, PT $200→$125; Jefferies PT cut to $140, later to $110; JPMorgan held Overweight but cut PT $210→$160; Goldman $171→$152).
- Defense-spending / margin durability doubts. Skepticism that 15%+ margins can persist amid budget uncertainty and a rising investment cycle.
Net: the stock screens near ~10x trailing / ~9-10x forward EPS versus a ~20x historical average — cheap enough that the bull case is now "is the bad news priced in?"
What consensus expects for Q2
| Metric |
Q2 FY25 (actual) |
Q2 FY26 (consensus) |
Implied Y/Y |
| Revenue |
$4,253M |
~$4,435M |
+~4% |
| Non-GAAP EPS |
$3.21 (record, +22%) |
~$2.90 |
~-9% |
| Adj. EBITDA margin |
15.2% (record) |
~13-14% |
Down |
This is the toughest comp of the year. Q2 FY25 was a record quarter — 15.2% adjusted EBITDA margin and 22% EPS growth — and it was flattered by a $25M insurance reimbursement for legal costs that will not repeat. On the Q1 call, CFO Chris Cage explicitly framed Q2 as roughly similar to Q1 on run-rate "maybe a small step down," with margin pressured by the absence of that insurance benefit and by rising near-term growth investments to lock in franchise positions (Military OneSource, My Service Treatment Record, and multiple Defense product lines). A single-digit EPS decline is therefore the expected, pre-communicated shape — a headline miss/beat matters less than the guide and Health commentary.
Key debate #1: Health — the whole story right now
Health is ~27% of revenue but carries the company's richest margins (Q1 FY26 non-GAAP operating margin ~24.2%), so any reset flows disproportionately to EPS. Watch for:
- VBA disability exam volumes. Management said Q1 volumes "remained high" and the VA is still burning down backlog. The bear case is these volumes normalize and a fourth vendor pressures share — the "overearning" thesis.
- The VBA recompete / Industry Day follow-through. A customer Industry Day was held in late May; investors will want any read on contract structure, timing, and Leidos's expected share going forward.
- DHMSM / MHS GENESIS extension. On the Q1 call, Tom Bell said he expected "near-term continuity through an extension mechanism" — but the mid-June DHA news suggests the customer wants a new lead integrator longer-term. This is the single most important qualitative update in the print. Any clarity (extension terms, transition timeline, revenue at risk) will move the stock.
- The offsets management is selling: the $456M Military OneSource directed award, the My Service Treatment Record AI pilot, and expansion into behavioral/rural health as the new "managed health" growth pillar. CFO framed FY26 Health as a "modest reset" with a growth trajectory beyond. Investors need evidence the growth pillars can backfill the exam/DHMSM risk.
Key debate #2: Margins and the investment ramp
- Q1 adj. EBITDA margin was 14.0% (vs 14.2% a year ago); FY guide is "mid-13%," implying margin steps down over the balance of the year as investments ramp and mix shifts toward lower-margin products/Entrust.
- Segment margin watch points from Q1: Defense non-GAAP OM fell to 8.3% (from 9.8%) on a fixed-price development program schedule delay (Space Wide Field of View / Tranche 1); Homeland non-GAAP OM slipped to 8.5% on changing requirements on a fixed-price program. Management expects both to improve as new higher-margin programs (IFPC, PAMS, ABAD) ramp — look for confirmation.
- CapEx cadence: management guided ~$350M for the year (a ~3x step-up) but spent only $31M in Q1. A Q2 acceleration would pressure free cash flow but signal the Defense production ramp is real.
Key debate #3: Full-year guidance
Current FY26 guide (raised at Q1, mostly on Entrust): Revenue $18.0-18.4B, adj. EBITDA margin mid-13%, non-GAAP EPS $12.10-12.50, OCF ~$1.8B.
- With Q1 non-GAAP EPS of $3.13 and Q2 consensus ~$2.90, the model requires a meaningful 2H acceleration — management insists Q3/Q4 is a "step function" up as post-shutdown procurement recovers. Credibility of that back-half hockey stick is the crux.
- Watch whether they hold, raise, or trim guidance, and how they frame the pending SES/Analogic security-products JV (expected to close in 2H; not yet in guidance — will remove SES revenue and instead book ~40% equity-method income).
Bookings, backlog and other watch items
- Book-to-bill: Q1 was a soft 0.8 (TTM 1.1x); backlog $48.4B ($9.6B funded). Management expects awards to "pick up significantly." A book-to-bill back above ~1.0x would help the recovery narrative; ~70% of the 12-month pipeline is new/takeaway business.
- Capital return: The board authorized a new 20M-share repurchase program (late July) and declared a $0.43 dividend; LDOS bought back ~$200M+ of stock in Q1. At a depressed price, buyback pace is a real EPS lever and a signal of management conviction.
- Balance sheet: gross leverage ~2.6x after the $2.4B Entrust deal; management has been paying down commercial paper faster than planned.
- Growth catalysts to listen for: Defense product scaling (small cruise missile / AGM-190A, MUSV maritime autonomy, ALPS/Golden Dome sensing, AirShield counter-UAS); the CoreWeave AI-cloud federal partnership; Entrust energy-infrastructure integration (targeting a $10B refreshed pipeline).
How I'd frame the reaction
- Bull case: Q2 lands in line (the weak comp is known), management reaffirms/tightens FY26, gives constructive DHMSM extension detail and reassures on VBA volumes, and leans on the buyback. At ~10x earnings with a bombed-out sentiment, that combination could spark a relief rally.
- Bear case: any incremental negative on DHMSM (confirmed loss of lead-integrator role, transition timeline), a Health margin reset worse than "modest," or a guidance trim — especially given the required 2H acceleration — would validate the derating and pressure the stock further.
- Base case: a pre-telegraphed "trough" quarter with a maintained full-year guide; the stock trades on the tone of Health/DHMSM commentary and book-to-bill more than on the printed EPS.
Bottom line: Numbers are almost secondary here. The market has already priced a Health reset; the swing factor is management's ability to quantify the DHMSM/VBA risk, defend the "mid-13s" margin floor, and make the second-half re-acceleration credible. Given the ~50% peak-to-trough drawdown, the risk/reward is asymmetric to clarity — good or bad.
Note: LDOS uses a fiscal calendar ending in early January; "Q2 FY2026" is the quarter ending ~early July 2026. All financials above are drawn from company releases and Q1 FY26 call commentary; consensus and analyst-action figures are from public news sources and are approximate.